Diagnostic procedures and management of fever in pediatric cancer patients;Fieber unklarer genese (FUO) bei kindern und jugendlichen mit onkologischen erkrankungen

Klinische Padiatrie

Volumn 217, Issue SUPPL. 1, 2005, Pages

  Laws, Hans Jürgen ^a,d   Ammann, R A ^b   Lehrnbecher, T ^c  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d Klinik für Kinder Onkologie Hämatologie und Klin Immunologie   (Germany)

Author keywords

Children; Fever of unknown origin; FUO; Oncology; Recommondation

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CILASTATIN PLUS IMIPENEM; GENTAMICIN; GLYCOPEPTIDE; IMIPENEM; MEROPENEM; METICILLIN; METRONIDAZOLE; PIPERACILLIN; SULBACTAM; TAZOBACTAM; TOBRAMYCIN;

ANTIBIOTIC THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER THERAPY; CHILDHOOD CANCER; DIAGNOSTIC PROCEDURE; FEBRILE NEUTROPENIA; FEVER; GRANULOCYTOPENIA; HUMAN; MORBIDITY; NONHUMAN; PRACTICE GUIDELINE; PSEUDOMONAS; REVIEW;

ADMINISTRATION, ORAL; ADOLESCENT; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; DRUG THERAPY, COMBINATION; EMPIRICISM; FEVER OF UNKNOWN ORIGIN; HUMANS; INFUSIONS, INTRAVENOUS; MICROBIAL SENSITIVITY TESTS; NEOPLASMS; NEUTROPENIA; OPPORTUNISTIC INFECTIONS; PRACTICE GUIDELINES; PROGNOSIS; SURVIVAL RATE;

EID: 28644444771     PISSN: 03008630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-872499     Document Type: Review

References (64)

1. Recommendations for preventing the spread of vancomycin resistance. Hospital Infection Control Practices Advisory Committee (HICPAC). Infect Control Hosp Epidemiol 1995; 16: 105-113
2. Agaoglu L, Devecioglu O, Anak S et al. Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey. J Chemother 2001; 13: 281-287
3. Ammann RA, Hirt A, Luthy AR et al. Predicting bacteremia in children with fever and chemotherapy-induced neutropenia. Pediatr Infect Dis J 2004; 23: 61-67
4. Ammann RA, Simon A, de Bont ES. Low risk episodes of fever and neutropenia in pediatric oncology: Is outpatient oral antibiotic therapy the new gold standard of care? Pediatr Blood Cancer 2005; 45: 244-247
5. Berger A, Kretzer V, Apfalter P et al. Safety evaluation of piperacillin/tazobactam in very low birth weight infants. J Chemother 2004; 16: 166-171
6. Bodey GP, Rodriguez V, Chang HY et al. Fever and infection in leukemic patients: a study of 494 consecutive patients. Cancer 1978; 41: 1610-1622
7. Chuang YY, Hung IJ, Yang CP et al. Cefepime versus ceftazidime as empiric monotherapy for fever and neutropenia in children with cancer. Pediatr Infect Dis J 2002; 21: 203-209
8. Cometta A, Kern WV, De Bock R et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 2003; 37: 382-389
9. Cometta A, Zinner S, de Bock R et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother 1995; 39: 445-452
10. Creutzig U, Henze G, Bielack S et al. Krebserkrankung bei Kindern; Erfolg durch einheitliche Therapiekonzepte seit 25 Jahren. Dtsch Arztblatt 2003; 100A: 842-852
11. Dompeling EC, Donnelly JP, Deresinski SC et al. Early identification of neutropenic patients at risk of grampositive bacteraemia and the impact of empirical administration of vancomycin. Eur J Cancer 1996; 32A: 1332-1339
12. Durack DT, Street AC. Fever of unknown origin - reexamined and redefined. Curr Clin Top Infect Dis 1991; 11: 35-51
13. Elting LS, Rubenstein EB, Rolston K et al. Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care. J Clin Oncol 2000; 18: 3699-3706
14. Elting LS, Rubenstein EB, Rolston KV et al. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997; 25: 247-259
15. Engelhard D, Elishoov H, Strauss N et al. Nosocomial coagulase-negative staphylococcal infections in bone marrow transplantation recipients with central vein catheter. A 5-year prospective study. Transplantation 1996; 61: 430-434
16. Erjavec Z, de Vries-Hospers HG, Laseur M et al. A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy. J Antimicrob Chemother 2000; 45: 843-849
17. Feld R. Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer: pros and cons. Clin Infect Dis 1999; 29: 503-507
18. Fleischhack G, Hartmann C, Simon A et al. Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer. J Antimicrob Chemother 2001; 47: 841-853
19. Fleischhack G, Schmidt-Niemann M, Wulff B et al. Piperacillin, beta-lactam inhibitor plus gentamicin as empirical therapy of a sequential regimen in febrile neutropenia of pediatric cancer patients. Support Care Cancer 2001; 9: 372-379
20. Flidel-Rimon O, Friedman S, Gradstein S et al. Reduction in multiresistant nosocomial infections in neonates following substitution of ceftazidime with piperacillin/tazobactam in empiric antibiotic therapy. Acta Paediatr 2003; 92: 1205-1207
21. Freifeld A, Marchigiani D, Walsh T et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999; 341: 305-311
22. Furno P, Bucaneve G, Del Favero A. Monotherapy or aminoglycoside- containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis 2002; 2: 231-242
23. Gobel V, Jurgens H, Thomas L et al. Microbial spectrum of blood and body cultures in febrile episodes of children under chemotherapy for treatment of malignant diseases. Pediatr Hematol Oncol 1987; 4: 7-13
24. Gorschluter M, Hahn C, Fixson A et al. Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison. Support Care Cancer 2003; 11: 362-370
25. Graf N, Gobel U. Clinical trials and studies of the German Society for Paediatric Oncology and Haematology (GPOH) and the European Directive for the Implementation of Good Clinical Practice in the Conduct of Clinical Trials. Klin Padiatr 2004; 216: 129-131
26. Groll AH, Lehrnbecher T. New antifungal drugs and the pediatric cancer patient: current status of clinical development. Klin Padiatr 2005; 217: 158-168
27. Hargrave DR, Hann II, Richards SM et al. Progressive reduction in treatment-related deaths in Medical Research Council childhood lymphoblastic leukaemia trials from 1980 to 1997 (UKALL VIII, X and XI). Br J Haematol 2001; 112: 293-299
28. Holdsworth M, Hanrahan J, Albanese B et al. Outpatient management of febrile neutropenia in children with cancer. Paediatr Drugs 2003; 5: 443-455
29. Hughes WT, Armstrong D, Bodey GP et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-751
30. Jacobs RF, Vats TS, Pappa KA et al. Ceftazidime versus ceftazidime plus tobramycin in febrile neutropenic children. Infection 1993; 21: 223-228
31. Jones GR, Konsler GK, Dunaway RP et al. Risk factors for recurrent fever after the discontinuation of empiric antibiotic therapy for fever and neutropenia in pediatric patients with a malignancy or hematologic condition. J Pediatr 1994; 124: 703-708
32. Katz JA, Bash R, Rollins N et al. The yield of routine chest radiography in children with cancer hospitalized for fever and neutropenia. Cancer 1991; 68: 940-943
33. Kebudi R, Gorgun O, Ayan I et al. Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors. Med Pediatr Oncol 2001; 36: 434-441
34. Klaassen RJ, Allen U, Doyle JJ. Randomized placebo-controlled trial of oral antibiotics in pediatric oncology patients at low-risk with fever and neutropenia [In Process Citation]. J Pediatr Hematol Oncol 2000; 22: 405-411
35. Klastersky J, Paesmans M, Rubenstein EB et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18: 3038-3051
36. Kline RM, Baorto EP. Treatment of peiatric febrile neutropenia in the era of vancomycin-resistant microbes. Pediatr Blood Cancer 2005; 44: 207-214
37. Korones DN, Hussong MR, Gullace MA. Routine chest radiography of children with cancer hospitalized for fever and neutropenia: is it really necessary? Cancer 1997; 80: 1160-1164
38. Kresken M, Hafner D. Drug resistance among clinical isolates of frequently encountered bacterial species in central Europe during 1975-1995. Study Group Bacterial Resistance of the Paul-Ehrlich-Society for Chemotherapy. Infection 1999; 27 (Suppl 2): S2-S8
39. Lehrnbecher T, Stanescu A, Kuhl J. Short courses of intravenous empirical antibiotic treatment in selected febrile neutropenic children with cancer. Infection 2002; 30: 17-21
40. Lehrnbecher T, Varwig D, Kaiser J et al. Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93. Leukemia 2004; 18: 72-77
41. Lidsky K, Hoyen C, Salvator A et al. Antibiotic-resistant gram-negative organisms in pediatric chronic-care facilities. Clin Infect Dis 2002; 34: 760-766
42. Link H, Blumenstengel K, Bohme A et al. [Antimicrobial therapy for fever of unknown origin in neutropenia. Standard recommendations of the Work Group of Infections in Hematology and Oncology of the German Association of Hematology and Oncology). Dtsch Med Wochenschr 1999; 124(Suppl 1): S3-S8
43. Link H, Bohme A, Comely OA et al. Antimicrobial therapy of unexplained fever in neutropenic patients-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 2003; 82 (Suppl 2): S105-S117
44. Maschmeyer G, Link H, Hiddemann W et al. [Empirical antimicrobial therapy in neutropenic patients. Results of a multicenter study by the Infections in Hematology Study Group of the Paul Ehrlich Society]. Med Klin (Munich) 1994; 89: 114-123
45. Maschmeyer G, Link H, Hiddemann W et al. Pulmonary infiltrations in febrile patients with neutropenia. Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study. Cancer 1994; 73: 2296-2304
46. Mullen CA. Ciprofloxacin in treatment of fever and neutropenia in pediatric cancer patients. Pediatr Infect Dis J 2003; 22: 1138-1142
47. Mullen CA, Petropoulos D, Roberts WM et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer 1999; 86: 126-134
48. Nurnberger W, Bonig H, Burdach S et al. Tolerability of piperacillin/tazobactam in children and adolescents after high dose radio-/chemotherapy and autologous stem cell transplantation. Infection 1998; 26: 65-67
49. Orudjev E, Lange BJ. Evolving concepts of management of febrile neutropenia in children with cancer. Med Pediatr Oncol 2002; 39: 77-85
50. Paganini H, Gomez S, Ruvinsky S et al. Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single-center, randomized, controlled trial in Argentina. Cancer 2003; 97: 1775-1780
51. Paganini HR, Sarkis CM, De Martino MG et al. Oral administration of cefixime to lower risk febrile neutropenic children with cancer. Cancer 2000; 88: 2848-2852
52. Paul M, Benuri-Silbiger I, Soares-Weiser K et al. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. Bmj 2004; 328: 668
53. Paul M, Soares-Weiser K, Grozinsky S et al. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropaenia. Cochrane Database Syst Rev 2003: CD003038
54. Petrilli AS, Dantas LS, Campos MC et al. Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial. Med Pediatr Oncol 2000; 34: 87-91
55. Ramphal R, Bolger M, Oblon DJ et al. Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazadime: A randomized prospective study. Antimicro Agents Chemother 1992; 36: 1062-1067
56. Renoult E, Buteau C, Turgeon N et al. Is routine chest radiography necessary for the initial evaluation of fever in neutropenic children with cancer? Pediatr Blood Cancer 2004; 43: 224-228
57. Santolaya ME, Villarroel M, Avendano LF et al. Discontinuation of antimicrobial therapy for febrile, neutropenic children with cancer: a prospective study. Clin Infect Dis 1997; 25: 92-97
58. Shenep JL, Flynn PM, Baker DK et al. Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer. Clin Infect Dis 2001; 32: 36-43
59. Silling G, Fegeler W, Roos N et al. Early empiric antifungal therapy of infections in neutropenic patients comparing fluconazole with amphotericin B/flucytosine. Mycoses 1999; 42 (Suppl 2): 101-104
60. Todeschini G, Franchini M, Tecchio C et al. Improved prognosis of Pseudomonas aeruginosa bacteremia in 127 consecutive neutropenic patients with hematologic malignancies. Int J Infect Dis 1998; 3: 99-104
61. Tunkel AR, Sepkowitz KA. Infections caused by viridans streptococci in patients with neutropenia. Clin Infect Dis 2002; 34: 1524-1529
62. Viscoli C, Castagnola E, Lint MT Van et al. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. Eur J Cancer 1996; 32A: 814-820
63. Wacker P, Halperin DS, Wyss M et al. Early hospital discharge of children with fever and neutropenia: a prospective study. J Pediatr Hematol Oncol 1997; 19: 208-211
64. Wehl G, Allerberger F, Heitger A et al. Trends in infection morbidity in a pediatric oncology ward, 1986-1995. Med Pediatr Oncol 1999; 32: 336-343